Teachers Retirement System of The State of Kentucky held its stake in Diplomat Pharmacy, Inc. (NYSE:DPLO) during the first quarter, Holdings Channel reports. The institutional investor owned 15,700 shares of the company’s stock at the end of the first quarter. Teachers Retirement System of The State of Kentucky’s holdings in Diplomat Pharmacy were worth $250,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Texas Permanent School Fund boosted its stake in Diplomat Pharmacy by 0.5% in the first quarter. Texas Permanent School Fund now owns 31,420 shares of the company’s stock worth $501,000 after buying an additional 164 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in Diplomat Pharmacy by 2.9% in the first quarter. Louisiana State Employees Retirement System now owns 17,700 shares of the company’s stock worth $282,000 after buying an additional 500 shares in the last quarter. Arizona State Retirement System boosted its stake in Diplomat Pharmacy by 2.3% in the first quarter. Arizona State Retirement System now owns 22,600 shares of the company’s stock worth $360,000 after buying an additional 500 shares in the last quarter. Blair William & Co. IL boosted its stake in Diplomat Pharmacy by 4.0% in the first quarter. Blair William & Co. IL now owns 17,489 shares of the company’s stock worth $238,000 after buying an additional 670 shares in the last quarter. Finally, OLD National Bancorp IN boosted its stake in Diplomat Pharmacy by 4.7% in the first quarter. OLD National Bancorp IN now owns 15,862 shares of the company’s stock worth $253,000 after buying an additional 708 shares in the last quarter. Institutional investors own 72.02% of the company’s stock.

Diplomat Pharmacy, Inc. (NYSE:DPLO) traded down 0.82% during mid-day trading on Friday, hitting $15.81. The stock had a trading volume of 257,066 shares. Diplomat Pharmacy, Inc. has a one year low of $12.25 and a one year high of $34.80. The stock has a market cap of $1.07 billion, a P/E ratio of 86.39 and a beta of 0.66. The company has a 50 day moving average price of $15.50 and a 200 day moving average price of $15.71.

Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. The firm had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.14 billion. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the firm posted $0.23 earnings per share. On average, equities analysts anticipate that Diplomat Pharmacy, Inc. will post $0.75 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Teachers Retirement System of The State of Kentucky Has $250,000 Position in Diplomat Pharmacy, Inc. (NYSE:DPLO)” was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/11/teachers-retirement-system-of-the-state-of-kentucky-has-250000-position-in-diplomat-pharmacy-inc-nysedplo.html.

A number of analysts have recently commented on DPLO shares. Leerink Swann reiterated a “market perform” rating and set a $18.00 target price (up previously from $16.00) on shares of Diplomat Pharmacy in a research report on Wednesday, May 17th. Zacks Investment Research upgraded Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Wednesday. Barclays PLC set a $20.00 target price on Diplomat Pharmacy and gave the stock a “buy” rating in a research report on Tuesday, May 9th. Cowen and Company lifted their target price on Diplomat Pharmacy from $12.00 to $17.00 and gave the stock a “market perform” rating in a research report on Tuesday, May 9th. Finally, BidaskClub cut Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $17.89.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.